Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMGU05N)

Drug Name
GSK598809 Drug Info
Indication
Disease Entry ICD 11 Status REF
Drug abuse 6C4G.1Z Phase 2 [1]
Cross-matching ID
PubChem CID
24743758
TTD Drug ID
DMGU05N

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D3 receptor (D3R) TT4C8EA DRD3_HUMAN Antagonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Dopamine D3 receptor (D3R) DTT DRD3 1.379 2.446 1.233 1.07
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Drug abuse
ICD Disease Classification 6C4G.1Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D3 receptor (D3R) DTT DRD3 2.84E-03 0.13 2
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01188967) Effectiveness of GSK598809, a Selective D3 Antagonist, Added to Cognitive Behavioral Therapy and Nicotine Replacement Therapy for Smoking Cessation and Prevention of Very Early Relapse to Smoking. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).